Investors

Positioned to deliver…

Seasoned management team and Board with extensive experience in R&D, manufacturing and commercialisation within the life sciences sector. 

In-house and external regulatory specialists supporting CE mark, WHO PQ and FDA 510(k) market clearance. 

IS0 13485: 2016 


Comprehensive proprietary IP portfolio  

Transformational point-of-care molecular diagnostic platform 

Long-standing, validating relationships with key advisers and partners


Strong product pipeline: respiratory panel, HPV, STIs  


 

 

Overview

QuantuMDx is an ambitious UK-based life science tools and diagnostics company. We have developed a highly innovative, portable molecular diagnostic platform, Q-POC™ which offers rapid, sample to answer, multiplexed testing within 30 minutes, at the point of care. 


Find out more

News

Our announcements, achievements and latest news

QuantuMDx confirm its diagnostic tests remain able to detect all known variants of COVID-19 including the new variant from South Africa, B.1.1.529

Following the detection of the variant B.1.1.529, we have performed a detailed analysis to fully assess the reliability of our existing tests

Read More

QuantuMDx secures £15 million equity investment from Vita Spring and enters into Cooperation Agreement discussions with Sansure Biotech

QuantuMDx secures £15 million equity investment from Vita Spring and enters into Cooperation Agreement discussions with Sansure Biotech.

Read More

QuantuMDx partners with Cignpost Diagnostics

QuantuMDx is partnering with Cignpost Diagnostics, a leading provider of COVID-19 workplace testing to the film & TV industry.

Read More

QuantuMDx launches Q-POC™ – a PCR diagnostic system

NEWCASTLE UPON TYNE, UK: QuantuMDx today announces the launch of Q-POC™ – a rapid, PCR point of care diagnostic system.…

Read More